Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system

Xingkui Xue, Xin Huang, Sonja E. Nodland, Lajos Mátés, Linan Ma, Zsuzsanna Izsvák, Zoltán Ivics, Tucker W. LeBien, R. Scott McIvor, John E. Wagner, Xianzheng Zhou

Research output: Contribution to journalArticle

88 Citations (Scopus)

Abstract

Here we report stable gene transfer in cord blood-derived CD34+ hematopoietic stem cells using a hyperactive nonviral Sleeping Beauty (SB) transposase (SB100X). In colony-forming assays, SB100X mediated the highest efficiency (24%) of stable Discosoma sp red fluorescent protein (DsRed) reporter gene transfer in committed hematopoietic progenitors compared with both the early-generation hyperactive SB11 transposase and the piggyBac transposon system (1.23% and 3.8%, respectively). In vitro differentiation assays further demonstrated that SB100X-transfected CD34+ cells can develop into DsRed+ CD4+CD8+ T (3.17%-21.84%; median, 7.97%), CD19+ B (3.83%-18.66%; median, 7.84%), CD56 +CD3- NK (3.53%-79.98%; median, 7.88%), and CD33 + myeloid (7.59%-15.63%; median, 9.48%) cells. SB100X-transfected CD34+ cells achieved approximately 46% engraftment in NOD-scid IL;cnull (NOG)mice.Twelve weeks after transplantation, 0.57% to 28.96% (median, 2.79%) and 0.49% to 34.50% (median, 5.59%) of total human CD45+ cells in the bone marrow and spleen expressed DsRed, including CD19+ B, CD14+ monocytoid, and CD33+ myeloid cell lineages. Integration site analysis revealedSBtransposon sequences in thehumanchromosomes of in vitro differentiated T, B, NK, and myeloid cells, as well as in human CD45+ cells isolated from bone marrow and spleen of transplanted NOG mice. Our results support the continuing development of SB-based gene transfer into humanhematopoietic stem cells as a modality for gene therapy.

Original languageEnglish (US)
Pages (from-to)1319-1330
Number of pages12
JournalBlood
Volume114
Issue number7
DOIs
StatePublished - Nov 19 2009

Fingerprint

Gene transfer
Beauty
Hematopoietic Stem Cells
Fetal Blood
Gene expression
Transposases
Blood
Myeloid Cells
Stem cells
Gene Expression
Bone Marrow Cells
Assays
Bone
Spleen
Gene therapy
Cell Lineage
Reporter Genes
Natural Killer Cells
Genetic Therapy
Genes

Cite this

Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. / Xue, Xingkui; Huang, Xin; Nodland, Sonja E.; Mátés, Lajos; Ma, Linan; Izsvák, Zsuzsanna; Ivics, Zoltán; LeBien, Tucker W.; McIvor, R. Scott; Wagner, John E.; Zhou, Xianzheng.

In: Blood, Vol. 114, No. 7, 19.11.2009, p. 1319-1330.

Research output: Contribution to journalArticle

Xue, Xingkui ; Huang, Xin ; Nodland, Sonja E. ; Mátés, Lajos ; Ma, Linan ; Izsvák, Zsuzsanna ; Ivics, Zoltán ; LeBien, Tucker W. ; McIvor, R. Scott ; Wagner, John E. ; Zhou, Xianzheng. / Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system. In: Blood. 2009 ; Vol. 114, No. 7. pp. 1319-1330.
@article{8afb2ee23c774f8d942052f7f25e32d5,
title = "Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system",
abstract = "Here we report stable gene transfer in cord blood-derived CD34+ hematopoietic stem cells using a hyperactive nonviral Sleeping Beauty (SB) transposase (SB100X). In colony-forming assays, SB100X mediated the highest efficiency (24{\%}) of stable Discosoma sp red fluorescent protein (DsRed) reporter gene transfer in committed hematopoietic progenitors compared with both the early-generation hyperactive SB11 transposase and the piggyBac transposon system (1.23{\%} and 3.8{\%}, respectively). In vitro differentiation assays further demonstrated that SB100X-transfected CD34+ cells can develop into DsRed+ CD4+CD8+ T (3.17{\%}-21.84{\%}; median, 7.97{\%}), CD19+ B (3.83{\%}-18.66{\%}; median, 7.84{\%}), CD56 +CD3- NK (3.53{\%}-79.98{\%}; median, 7.88{\%}), and CD33 + myeloid (7.59{\%}-15.63{\%}; median, 9.48{\%}) cells. SB100X-transfected CD34+ cells achieved approximately 46{\%} engraftment in NOD-scid IL;cnull (NOG)mice.Twelve weeks after transplantation, 0.57{\%} to 28.96{\%} (median, 2.79{\%}) and 0.49{\%} to 34.50{\%} (median, 5.59{\%}) of total human CD45+ cells in the bone marrow and spleen expressed DsRed, including CD19+ B, CD14+ monocytoid, and CD33+ myeloid cell lineages. Integration site analysis revealedSBtransposon sequences in thehumanchromosomes of in vitro differentiated T, B, NK, and myeloid cells, as well as in human CD45+ cells isolated from bone marrow and spleen of transplanted NOG mice. Our results support the continuing development of SB-based gene transfer into humanhematopoietic stem cells as a modality for gene therapy.",
author = "Xingkui Xue and Xin Huang and Nodland, {Sonja E.} and Lajos M{\'a}t{\'e}s and Linan Ma and Zsuzsanna Izsv{\'a}k and Zolt{\'a}n Ivics and LeBien, {Tucker W.} and McIvor, {R. Scott} and Wagner, {John E.} and Xianzheng Zhou",
year = "2009",
month = "11",
day = "19",
doi = "10.1182/blood-2009-03-210005",
language = "English (US)",
volume = "114",
pages = "1319--1330",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "7",

}

TY - JOUR

T1 - Stable gene transfer and expression in cord blood-derived CD34+ hematopoietic stem and progenitor cells by a hyperactive Sleeping Beauty transposon system

AU - Xue, Xingkui

AU - Huang, Xin

AU - Nodland, Sonja E.

AU - Mátés, Lajos

AU - Ma, Linan

AU - Izsvák, Zsuzsanna

AU - Ivics, Zoltán

AU - LeBien, Tucker W.

AU - McIvor, R. Scott

AU - Wagner, John E.

AU - Zhou, Xianzheng

PY - 2009/11/19

Y1 - 2009/11/19

N2 - Here we report stable gene transfer in cord blood-derived CD34+ hematopoietic stem cells using a hyperactive nonviral Sleeping Beauty (SB) transposase (SB100X). In colony-forming assays, SB100X mediated the highest efficiency (24%) of stable Discosoma sp red fluorescent protein (DsRed) reporter gene transfer in committed hematopoietic progenitors compared with both the early-generation hyperactive SB11 transposase and the piggyBac transposon system (1.23% and 3.8%, respectively). In vitro differentiation assays further demonstrated that SB100X-transfected CD34+ cells can develop into DsRed+ CD4+CD8+ T (3.17%-21.84%; median, 7.97%), CD19+ B (3.83%-18.66%; median, 7.84%), CD56 +CD3- NK (3.53%-79.98%; median, 7.88%), and CD33 + myeloid (7.59%-15.63%; median, 9.48%) cells. SB100X-transfected CD34+ cells achieved approximately 46% engraftment in NOD-scid IL;cnull (NOG)mice.Twelve weeks after transplantation, 0.57% to 28.96% (median, 2.79%) and 0.49% to 34.50% (median, 5.59%) of total human CD45+ cells in the bone marrow and spleen expressed DsRed, including CD19+ B, CD14+ monocytoid, and CD33+ myeloid cell lineages. Integration site analysis revealedSBtransposon sequences in thehumanchromosomes of in vitro differentiated T, B, NK, and myeloid cells, as well as in human CD45+ cells isolated from bone marrow and spleen of transplanted NOG mice. Our results support the continuing development of SB-based gene transfer into humanhematopoietic stem cells as a modality for gene therapy.

AB - Here we report stable gene transfer in cord blood-derived CD34+ hematopoietic stem cells using a hyperactive nonviral Sleeping Beauty (SB) transposase (SB100X). In colony-forming assays, SB100X mediated the highest efficiency (24%) of stable Discosoma sp red fluorescent protein (DsRed) reporter gene transfer in committed hematopoietic progenitors compared with both the early-generation hyperactive SB11 transposase and the piggyBac transposon system (1.23% and 3.8%, respectively). In vitro differentiation assays further demonstrated that SB100X-transfected CD34+ cells can develop into DsRed+ CD4+CD8+ T (3.17%-21.84%; median, 7.97%), CD19+ B (3.83%-18.66%; median, 7.84%), CD56 +CD3- NK (3.53%-79.98%; median, 7.88%), and CD33 + myeloid (7.59%-15.63%; median, 9.48%) cells. SB100X-transfected CD34+ cells achieved approximately 46% engraftment in NOD-scid IL;cnull (NOG)mice.Twelve weeks after transplantation, 0.57% to 28.96% (median, 2.79%) and 0.49% to 34.50% (median, 5.59%) of total human CD45+ cells in the bone marrow and spleen expressed DsRed, including CD19+ B, CD14+ monocytoid, and CD33+ myeloid cell lineages. Integration site analysis revealedSBtransposon sequences in thehumanchromosomes of in vitro differentiated T, B, NK, and myeloid cells, as well as in human CD45+ cells isolated from bone marrow and spleen of transplanted NOG mice. Our results support the continuing development of SB-based gene transfer into humanhematopoietic stem cells as a modality for gene therapy.

UR - http://www.scopus.com/inward/record.url?scp=70349320475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70349320475&partnerID=8YFLogxK

U2 - 10.1182/blood-2009-03-210005

DO - 10.1182/blood-2009-03-210005

M3 - Article

VL - 114

SP - 1319

EP - 1330

JO - Blood

JF - Blood

SN - 0006-4971

IS - 7

ER -